Oral Delivery of Parathyroid Hormone Using a Triple-Padlock Nanocarrier for Osteoporosis via an Enterohepatic Circulation Pathway

• Published in: ACS applied materials & interfaces Vol. 13; no. 20; pp. 23314 - 23327
• Main Authors: An, Jeong Man, Shahriar, S. M. Shatil, Hwang, Yong Hwa, Hwang, Seung Rim, Lee, Dong Yun, Cho, Sungpil, Lee, Yong-kyu
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 26.05.2021
• Subjects: Biological and Medical Applications of Materials and Interfaces; parathyroid hormone; nanoparticle; and enterohepatic recycling pathway; osteoporosis; oral delivery
• ISSN: 1944-8244; 1944-8252
• DOI: 10.1021/acsami.0c22170

Intermittent subcutaneous (S.C.) injection of teriparatide [PTH (1–34)] is one of the effective therapies to cure osteoporosis. However, a long-term repeated administration of teriparatide by S.C. to the patients is highly challenging. Herein, a triple padlock nanocarrier prepared by a taurocholic acid-conjugated chondroitin sulfate A (TCSA) is designed to develop an oral dosage form of recombinant human teriparatide (rhPTH). Oral administration of TCSA/rhPTH to the bilateral ovariectomized (OVX) rats resulted in the recovery of the bone marrow density and healthy serum bone parameters from the severe osteoporotic conditions. Also, it enhanced new bone formation in the osteoporotic tibias. This triple padlock oral delivery platform overcame the current barriers associated with teriparatide administration and exhibited a promising therapeutic effect against osteoporosis.